With the start of its second clinical trial, NexImmune expands development of its unique non-genetically engineered T cell immunotherapies across a range of hematologic malignancies GAITHERSBURG, Md., Oct. 06, 2020…
Read More
Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics
Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments Triumvira’s T-cell therapies have transformative potential as a new type of cancer treatment…
Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led by the Perceptive Xontogeny Venture Fund BALTIMORE, MD, June 24,…
GAITHERSBURG, MD – June 1, 2020 – NexImmune, a clinical-stage biopharma company advancing a new generation of nanoparticle-based therapies for targeted immune system response, today announced that John Trainer, Chief Financial…
The Board and Chief Executive Officer of Cereno Scientific AB here with present the Interim Report for the first quarter 2020. Summary of the Interim Report Cereno Scientific Group (2020-01-01…
Cereno Scientific develops innovative medicines for cardiovascular and rare diseases related to fibrosis, thrombosis, inflammation and high blood pressure in the lung as well as systemically. As a step towards…
Cereno Scientific develops innovative drugs for cardiovascular diseases, with a broadened focus on thrombosis and rare fibrosis-related cardiovascular diseases. Recently, the company’s lead candidate CS1 received Orphan Drug Designation from the FDA for the…
Cereno Scientific is accelerating the building of a platform of drug candidates in epigenetic modulation, by HDAC inhibition, for cardiovascular and rare diseases. On March 10, the company’s main candidate…
GAITHERSBURG, MD — January 08, 2020 – NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veterans Han Myint,…
BALTIMORE, MD – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and other…
